Nurix Therapeutics, Inc.
NRIX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001549595
In the last 90 days, Nurix Therapeutics, Inc. insiders filed 0 open-market purchases and 10 sales; 211 institutions reported holding it in 13F filings for Q2 2026, worth $2.84B in total; ARK Invest is the only superinvestor holding it.
13F holders, Q2 2021
Institutional positions in Nurix Therapeutics, Inc. as of Jun 30, 2021. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 104
- +4 vs. Q1 2021
- Shares held
- 39.5M
- −1.53M (−3.7%) vs. Q1 2021
- Total value
- $1.05B
- −$227.6M (−17.8%) vs. Q1 2021
- New holders
- 17
- 53 more added
- Sold out
- 13
- 16 more reduced
1 institution that held it in Q1 2021 haven't filed for Q2 2021 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q1 2021: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting NRIX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 211 | $2.84B |
| Q1 2026 | 196 | $1.81B |
| Q4 2025 | 182 | $2.15B |
| Q3 2025 | 173 | $783.3M |
| Q2 2025 | 164 | $1.01B |
| Q1 2025 | 170 | $1.01B |
| Q4 2024 | 175 | $1.53B |
| Q3 2024 | 172 | $1.53B |
| Q2 2024 | 174 | $1.36B |
| Q1 2024 | 139 | $721.3M |
| Q4 2023 | 131 | $475.6M |
| Q3 2023 | 129 | $352.5M |
| Q2 2023 | 126 | $435.7M |
| Q1 2023 | 124 | $376.6M |
| Q4 2022 | 119 | $468.6M |
| Q3 2022 | 118 | $561.0M |
| Q2 2022 | 106 | $568.4M |
| Q1 2022 | 117 | $565.6M |
| Q4 2021 | 125 | $1.17B |
| Q3 2021 | 113 | $1.18B |
| Q2 2021 | 104 | $1.05B |
| Q1 2021 | 101 | $1.29B |
Institutions, Q2 2021
Shares, value and share of portfolio for each institution holding Nurix Therapeutics, Inc.; share changes are against Q1 2021.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Baker Bros. Advisors LP | 2,454,082 | $65.1M | 0.29% | 00.0% | Unchanged |
| Redmile Group, LLC | 3,190,077 | $84.6M | 1.25% | −124,040−3.7% | Reduced |
| TRV GP III, LLC | 3,422,549 | $90.8M | 15.85% | −1,085,784−24.1% | Reduced |
| Price T Rowe Associates Inc | 4,051,478 | $107.5M | 0.01% | +957,773+31.0% | Added |
| The Column Group LLC | 0 | $0 | 0.00% | −5,383,333−100.0% | Sold out |
| Pinz Capital Management, LP | 0 | $0 | 0.00% | −72,459−100.0% | Sold out |
| Hamilton Lane Advisors LLC | 0 | $0 | 0.00% | −49,533−100.0% | Sold out |
| Bank Julius Baer & Co. Ltd, Zurich | 0 | $0 | 0.00% | −35,593−100.0% | Sold out |
| JS Capital Management LLC | 0 | $0 | 0.00% | −29,766−100.0% | Sold out |
| California Public Employees Retirement System | 0 | $0 | 0.00% | −22,600−100.0% | Sold out |
| American Financial Group Inc | 0 | $0 | 0.00% | −14,884−100.0% | Sold out |
| Trexquant Investment LP | 0 | $0 | 0.00% | −12,337−100.0% | Sold out |
| Laurion Capital Management LP | 0 | $0 | 0.00% | −7,000−100.0% | Sold out |
| Exane Derivatives | 0 | $0 | 0.00% | −2,300−100.0% | Sold out |
| STRS Ohio | 0 | $0 | 0.00% | −2,200−100.0% | Sold out |
| Pacer Advisors, Inc. | 0 | $0 | 0.00% | −1,581−100.0% | Sold out |
| Bank of Montreal | 0 | $0 | 0.00% | −709−100.0% | Sold out |
| WestHill Financial Advisors, Inc. | – | – | – | – | Not filed |